Abstract
There is great enthusiasm for lung cancer screening using low-dose computed tomography following the publication of the results of the National Lung Screening Trial (NLST). However, the early benefit reported in NLST has not been seen in three small European trials that have reported lung cancer mortality. In addition, there are a number of potential harms from LDCT screening, some of which will be reviewed.